Clinical outcomes of second relapsed and refractory first relapsed paediatric AML
العنوان: | Clinical outcomes of second relapsed and refractory first relapsed paediatric AML |
---|---|
المؤلفون: | Tara White, Gertjan Kaspers, Jonas Abrahamsson, Nira Arad‐Cohen, Daniela Cianci, Jose Fernandez, Shau‐Yin Ha, Henrik Hasle, Barbara De Moerloose, C. Michel Zwaan, Bianca F. Goemans |
المساهمون: | Pediatrics, Pediatric surgery, CCA - Cancer Treatment and quality of life |
المصدر: | White, T, Kaspers, G, Abrahamsson, J, Arad-Cohen, N, Cianci, D, Fernandez, J, Ha, S-Y, Hasle, H, de Moerloose, B, Zwaan, C M & Goemans, B F 2022, ' Clinical outcomes of second relapsed and refractory first relapsed paediatric AML : A retrospective study within the NOPHO-DB SHIP consortium ', British Journal of Haematology, vol. 197, no. 6, pp. 755-765 . https://doi.org/10.1111/bjh.18039 BRITISH JOURNAL OF HAEMATOLOGY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname British Journal of Haematology, 197(6), 755-765. Wiley-Blackwell Publishing Ltd White, T, Kaspers, G, Abrahamsson, J, Arad-Cohen, N, Cianci, D, Fernandez, J, Ha, S Y, Hasle, H, De Moerloose, B, Zwaan, C M & Goemans, B F 2022, ' Clinical outcomes of second relapsed and refractory first relapsed paediatric AML : A retrospective study within the NOPHO-DB SHIP consortium ', British Journal of Haematology, vol. 197, no. 6, pp. 755-765 . https://doi.org/10.1111/bjh.18039 British Journal of Haematology, 197(6), 755-765. Wiley-Blackwell |
بيانات النشر: | Wiley-Blackwell Publishing Ltd, 2022. |
سنة النشر: | 2022 |
مصطلحات موضوعية: | relapse, therapy, paediatric acute myeloid leukaemia, CHILDREN, ACUTE MYELOID-LEUKEMIA, Hematology, Prognosis, GEMTUZUMAB OZOGAMICIN, survival, FLT3 MUTATIONS, Leukemia, Myeloid, Acute, refractory disease, Treatment Outcome, Recurrence, Medicine and Health Sciences, Humans, Neoplasm Recurrence, Local, Child, Retrospective Studies |
الوصف: | As treatments for second relapsed and refractory first relapsed paediatric AML transition from purely palliative to more commonly curative in nature, comparative data is necessary for evaluating the effectiveness of emerging treatment options. Furthermore, little is known about predictors of prognosis following third-line therapy. From 2004 until 2019, 277 of the 869 patients enrolled in NOPHO-DB SHIP consortium trials experienced a first relapse and, of these patients, 98 experienced refractory first relapse and 59 a second relapse. Data on patient and disease characteristics within this cohort of 157 patients was analysed to determine probability of overall survival (pOS) and to identify factors influencing survival. Data on early treatment response and complete remission were not available. One and 5-year pOS were 22 ± 3% and 14 ± 3%, respectively. There was no statistically significant difference in survival between refractory first relapsed and second relapsed AML. Factors influencing prognosis included: late relapse, type of third-line treatment, FLT3 mutational status, and original treatment protocol. These data provide a baseline for evaluating the effectiveness of emerging therapies for the treatment of children with refractory first relapsed and second relapsed paediatric AML and evidence that select patients receiving third-line therapy can be cured. |
وصف الملف: | application/pdf |
اللغة: | English |
تدمد: | 1365-2141 0007-1048 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e87c8ac76b414dc4c88ff1b7d8a16594 https://pure.eur.nl/en/publications/a2ceff01-4b8c-4cb6-8f45-853dc3bd41c4 |
حقوق: | OPEN |
رقم الأكسشن: | edsair.doi.dedup.....e87c8ac76b414dc4c88ff1b7d8a16594 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 13652141 00071048 |
---|